In this talk Prof. Taylor presents the results of the CHD (Coronary Health in Diabetics) study, a randomized clinical trial on rosiglitazone vs. metformin in type 2 diabetic patients.

The insulin-sensitising antidiabetic agent metformin was shown to reduce cardiovascular outcomes in the UKPD Study, and it remains to be seen what are the effects on cardiovascular risk of the insulin-sensitising thiazolidinediones such as rosiglitazone. However, rosiglitazone and metformin have different drug mechanisms that may lead to differences in their anti-inflammatory and anti-atherosclerosis effects, and this has implications for their potential relative effects on cardiovascular outcomes, says Prof. Taylor.

In the present CHD Study, close to 100 type 2 diabetic patients with suboptimally controlled diabetes on a sulfonylurea or diet control were randomized to rosiglitazone 4mg daily or metformin 850mg twice daily. The study sought to compare changes in C-reactive protein and carotid intimal-medial thickness (CIMT) after 24 weeks of treatment. Prof. Taylor describes the study design and the observed effects of these agents in terms of glycemic control, lipids, the differential effects on CRP levels and changes in CIMT, and finally the implications of the study findings.

Copyright © 2006 E-MedHosting.com Inc.

After viewing this presentation the participant will be able to discuss:

- Effects of rosiglitazone vs. metformin in type 2 diabetic patients:
- -> Glycemic control
- -> Changes in CRP
- -> Changes in CIMT
- Implications of the CHD study